Episode
EP Edge Journal Watch — Issue 9 Redefining Ventricular Tachycardia Care: From Noninvasive Radioablation to Leadless, Modular, and Drug-Based Strategies
- Podcast
- EP Edge Journal Watch
- Published
- Feb 2, 2026
- Duration seconds
- 766
- Processing state
not_requested- Canonical source
- https://share.transistor.fm/s/40e18522
Actions
POST https://stenobird.com/v1/public/podcasts/ep-edge-journal-watch-7561379/episodes/ep-edge-journal-watch-issue-9-redefining-ventricular-tachycardia-care-from-noninvasive-radioablation-to-leadless-modular-and-drug-based-strategies/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/ep-edge-journal-watch-7561379/ep-edge-journal-watch-issue-9-redefining-ventricular-tachycardia-care-from-noninvasive-radioablation-to-leadless-modular-and-drug-based-strategies.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
In EP Edge Journal Watch – Issue 9 (February 2026) , we take a comprehensive, clinically grounded look at the evolving management of ventricular tachycardia (VT) —from last-line noninvasive therapies to next-generation devices, pharmacologic strategy, and infection prevention. This episode critically reviews the STRA-MI-VT trial , examining stereotactic arrhythmia radioablation (STAR) for refractory VT with a unique focus on coronary safety using serial coronary CT angiography . We explore why early VT suppression occurs after radioablation and what emerging mechanistic data suggest about electrophysiologic remodeling beyond fibrosis . We then turn to contemporary VT decision-making with a deep dive into the VANISH2 substudy , comparing first-line catheter ablation with antiarrhythmic drug therapy, highlighting where ablation clearly outperforms sotalol and rivals amiodarone—without long-term extracardiac toxicity. Next, we examine modular defibrillation systems combining subcutaneous ICDs with leadless antitachycardia pacing , unpacking ATP effectiveness, complication rates, and the critical nuance behind so-called “inappropriate” therapies. We also review the latest data on dual-chamber leadless pacing , demonstrating high real-world AV synchrony and outlining what questions remain unanswered. The episode concludes with two essential but often under-discussed domains: Why antiarrhythmic drugs still matter in 2026 , using updated EHRA frameworks for safer, more rational use What the CHLOVIS trial teaches us about CIED infection prevention—and why skin antisepsis alone is not the decisive factor As always, EP Edge Journal Watch prioritizes clinical context, trial design, limitations, and practical implications , helping electrophysiologists cut through signal versus no…